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IFN = interferon; IL = interleukin; JAK = Janus activated kinase; mAb = monoclonal antibody; PIAS = protein inhibitors of activated STATs; SOCS =
suppressors of cytokine signaling; STAT = signal transducer and activator of transcription.
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Abstract
In the late 1960s, the essential role played by T cells in antibody
production was reported. This led to our hypothesis that certain
molecules would have to be released from T cells to effect the
stimulation of B cells. This hypothesis was shown to be true. There
were certain factors present in the culture supernatant of T cells
that induced proliferation and differentiation of B cells. The factor
that induced B cells to produce immunoglobulins was initially
named B cell stimulatory factor-2. The cDNA encoding the human
B cell stimulatory factor-2 was cloned in 1986. At the same time,
IFN-β2 and a 26 kDa protein in the fibroblasts were independently
cloned and found to be identical to B cell stimulatory factor-2.
Later, a hybridoma/plasmacytoma growth factor and a hepatocyte
stimulating factor were also proven to be the same molecule as B
cell stimulatory factor-2. Various names were used for this single
molecule because of its multiple biological activities, but these
have all been unified and the molecule is now known as IL-6. Since
the discovery of IL-6, rapid progress has been made in our
understanding of IL-6 activities, the IL-6 receptor system and the
IL-6 signal transduction mechanism. More importantly, it has been
shown to be involved in a number of diseases such as rheumatoid
arthritis and Castleman's disease. When taking into account all the
accumulated basic research on the various aspects of this
molecule, it appeared that blocking the activity of IL-6 was a
feasible, new therapeutic approach for chronic inflammatory
diseases.
Introduction
Interactions between T and B cells during antibody
production were reported in 1968 [1,2], and it was theorized
that certain molecules are released from T cells and stimulate
B cells to produce antibodies. Activities that induce
proliferation and differentiation of B cells were observed in
supernatants of cultured T cells. The molecules responsible
for these activities were subsequently discovered by our
group and termed B cell growth factors and/or B cell
differentiation factors. Table 1 summarizes the research that
subsequently led to the characterization of factors involved in
the interactions between T and B cells.
Discovery of interleukin-6
In 1986 one of these factors was cloned and studied, and it
is now referred to as IL-6. This molecule possesses a wide
range of activities, and as a result laboratories used various
different names to refer to it, depending on their research
interests. It has been termed B cell stimulatory factor-2 and
was considered a novel IFN (IFN-β2), but studies with
recombinant IL-6 and anti-IL-6 antibody demonstrated that
IL-6 had no IFN activity [3]. The molecule exhibited a strong
stimulatory effect on growth of murine plasmacytoma [4] and
human myeloma [5], and was studied under the names
hybridoma plasmacytoma growth factor and hepatocyte
stimulating factor, which induces acute phase reactions [6,7].
Moreover, because it induces differentiation of myeloid pre-
cursors, it has been referred to as macrophage granulocyte
inducer type 2 [8]. In addition, IL-6 plays a key role in
inflammation, being the main inducer of C-reactive protein,
fibrinogen and serum amyloid A protein, as well as other
factors.
The activities described above were confirmed using IL-6
transgenic mouse models, revealing massive stimulation of
plasma cells in the spleen and lymph nodes. Transgenic
expression of IL-6 in BALB/c mice induced monoclonal
transplantable plasmacytoma, showing that IL-6 functions as
a plasmacytoma/myeloma growth factor. A study conducted
in an IL-6 knockout mouse model [9] revealed that, compared
with wild type, the antiviral antibody response was inhibited
by more than 90% following immunization with a vesicular
stomatitis virus. In a parallel experiment turpentine injection
induced strong inflammation, but, once again, in the IL-6
knockout mice almost 90% of this acute phase response was
blocked. These experiments confirm that IL-6 functions as a B
cell stimulatory factor to induce antibody production and as a
hepatocyte stimulatory factor to induce acute phase
reactions.
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As well as the functions described above, IL-6 has various
other biological activities (exemplified by the numerous
abbreviations used to describe IL-6). IL-6 is a pleiotropic
cytokine that influences antigen-specific immune responses
and inflammatory reactions. It has also been shown to induce
T cell growth and cytotoxic T cell differentiation by
augmenting IL-2 receptor expression [10] and IL-2
production [11]. IL-6 also induces proliferation of thymocytes
and probably plays a role in the development of thymic
T cells. In haematopoiesis, IL-6 acts synergistically with IL-3
to support the formation of multilineage blast cell colonies,
and it also induces macrophage differentiation and mega-
karyocyte differentiation [12]. IL-6 has profound effects on
bone and can induce osteoclast differentiation and activation
in vitro [13]. It appears to be involved in synovial inflammation
and in damage to peri-articular cartilage and bone. A
correlation has also been identified between serum IL-6 levels
and the severity of radiographic destruction [14]. Further-
more, it has been demonstrated to decrease aggrecan
protein and type II collagen production by chondrocytes [15].
IL-6 induces endothelial expression of adhesion molecules
and endothelial production of monocyte chemoattractant
protein-1 [16], a chemokine that is responsible for monocyte
recruitment. Moreover, IL-6 knockout mice exhibit impaired
leucocyte accumulation at the site of inflammation [16] and
defective transition to a chronic mononuclear cell infiltrate
[17]. It is also involved in the recruitment of mesenchymal
vascular cells and neoangiogenesis in vivo [18], and has
been shown to induce proliferation of synovial fibroblasts
[19]. Finally, IL-6 appears to be involved in damage to
cartilage and bone [20].
Interleukin-6 receptor system
Following the cloning of the cDNA of IL-6, the structure and
signaling function of the IL-6 receptor was studied. The IL-6
receptor system has an unusual organization. It consists of
two polypeptide chains [21]: an 80 kDa IL-6 receptor and a
130 kDa signal transducer (gp130). The 80 kDa receptor
exists in two forms, namely the transmembrane form and a
soluble form. The transmembrane form has a short
intracytoplasmic region and, upon stimulation by binding of
the IL-6 molecule, triggers an association with gp130. The
soluble receptor can form a stimulatory complex with IL-6,
which can associate with gp130 and trigger cellular events
called trans-signaling. The gp130 has a transmembrane
domain and is responsible for transducing the signal across
the membrane. It is worth noting that the gp130 is expressed
ubiquitously in tissues [11] and is used in the signaling of
many other members of the IL-6 family of cytokines, including
leukaemia inhibitory factor, ciliary neurotrophic factor, onco-
statin M, IL-11 and cardiotropin-1 [22-26]. The sharing of the
gp130 molecule by other IL-6 superfamily cytokines may
explain their functional redundancy. This can also be seen
within the other cytokine systems, for example IL-3, IL-5 and
granulocyte-macrophage colony-stimulating factor, and the
group of interleukins (IL-2, IL-4, IL-7, IL-9 and IL-15); both
groups use a common receptor component.
IL-6 and its receptor interact to form a complex consisting of
two IL-6 molecules plus two IL-6 receptor proteins and two
gp130 proteins. The dimerized gp130 then transduces the
signals. It is worth noting that the soluble IL-6 receptor also
exhibits an agonistic effect in complex with IL-6 and can
couple with the gp130 to effect transduction.
One of the difficulties in understanding the mechanism of
action of gp130 arises from the fact that it does not possess
a specific catalytic domain. This issue was resolved with the
discovery of the Janus activated kinase (JAK)-signal
transducer and activator of transcription (STAT) pathway;
these catalytic molecules associate with the cytokine
receptors [27]. The signaling has now been completely
elucidated. Activation of gp130 leads to the activation of the
intracytoplasmic JAK tyrosine kinases (Janus family tyrosine
kinases). Within minutes of IL-6 stimulation, these kinases
cause induction of tyrosine phosphorylation and recruitment
of STAT3, which dimerizes and is translocated to the nucleus
and leads to gene expression.
Regulation
IL-6 is essential for regulation of the immune process; however,
overproduction of the cytokine leads to inflammation and disease
(such as rheumatoid arthritis, systemic juvenile arthritis and
Crohn’s disease). As a result, the cytokine must be regulated to
control both the magnitude and duration of response.
IL-6 signaling systems are regulated by negative feedback by
the suppressors of cytokine signaling (SOCS) and the
protein inhibitors of activated STATs (PIAS). IL-6/IL-6
receptor interaction leads to activation of STAT3, which then
targets SOCS-1. The SOCS-1 molecule then binds to the
Table 1
A selection of published research resulting in the
characterization of factors involved in T/B cell interactions
Finding References
Discovery of soluble factors enhancing antibody  [53-55]
production 
Discovery of a T cell replacing factor [56]
Induction of immunoglobulin production in B  [57,58]
cells using rabbit lymphocytes or murine B cells
Two factors involved in B cell growth and B cell  [59]
differentiation
BCGF [60]
BCGF-II induced growth of and IgM production in  [61]
murine B cells (now IL-5)
BSF-1 cloned (now IL-4) [10]
BCDF/BSF-2 (IL-6) [62]
BCDF, B cell differentiation factor; BCGF, B cell growth factor; BSF,
B cell stimulatory factor; IL, interleukin.Page 3 of 6
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JAK tyrosine kinase and acts as a negative regulator of
gp130 signal transduction. SOCS-1, SOCS-2 and SOCS-3
are induced by several cytokines including IL-6, IFN-γ, IL-4,
and granulocyte colony-stimulating factor and several other
factors, and they inhibit cytokine-activated JAK/STAT signal
pathways (Fig. 1).
SOCS-1 directly interacts with JAKs and so inhibits their
catalytic activity, whereas SOCS-3 inhibits cytokine signaling
by binding to the receptor complex. In the IL-6 signal
pathway, SOCS-1 deficient mice have an intact IL-6 signaling
pathway, suggesting that SOCS-3 may act as a crucial
inhibitor of IL-6 signaling in vivo. PIASs constitute a family of
constitutively expressed negative regulators of STATs. PIAS-
3 associates specifically with activated STAT3 but not with
STAT1, resulting in blockade of all STAT3-mediated gene
transcription [28]. PIAS-3 is especially well known as an
inhibitor of IL-6 signaling in M1 cell lines (a mouse myeloid
leukaemia cell line).
Constitutive expression of PIAS proteins implies that their
physiological role may differ from that of SOCS proteins,
which are transiently induced by cytokine stimulation.
However, the differences in physiological role between these
two proteins are yet to be established.
Interleukin-6 overproduction and disease
A variety of studies have demonstrated that overproduction of
IL-6 contributes to the pathogenesis of various autoimmune
and inflammatory diseases. (For a review of IL-6 in auto-
immune disease and chronic inflammatory proliferative
disease, see the article by Ishihara and Hirano [29].) That IL-6
is involved in autoimmunity was first implied by the facts that
patients with cardiac myxoma frequently exhibit autoimmune
symptoms and that cardiac myxoma cells produce IL-6 [30].
Also, synovial fluid from patients with rheumatoid arthritis
contain elevated levels of IL-6 [31].
Since those early findings, several lines of evidence have
been reported that suggest the involvement of IL-6 in auto-
immune disease, chronic inflammatory proliferative disease
and B cell malignancy, as well as Castleman’s disease, and
plasmacytoma/multiple myeloma [32]. Furthermore, IL-6 is
required for experimentally induced autoimmune diseases,
including type II collagen-induced arthritis and antigen-
induced arthritis [33-35], myelin oligodendrocyte protein-
induced experimental autoimmune encephalomyelitis [36,37],
and pristane-induced autoantibody production [38]. These
findings, together with accumulating evidence from a large
body of clinical studies, suggest that IL-6 dependent
signaling pathways are involved in the pathogenesis of
experimentally induced autoimmune diseases and of naturally
occurring autoimmune diseases. However, how and at what
levels IL-6 plays its roles in the complex processes of these
diseases remain unknown.
Based on the findings described above, the potentially
therapeutic strategy of blocking the IL-6 signaling pathway
seemed logical and appealing. One approach that has been
tested was inhibition of the IL-6 molecule itself. However, use
of mAbs to human IL-6 in the clinical setting has yielded
unsatisfactory results. Administration of a mAb against IL-6
leads to persistence and accumulation of the cytokine in the
circulation in the form of immune complexes, increasing the
half-life of IL-6. This prevents such a single mAb to IL-6 from
neutralizing the effects of chronic overproduction of IL-6 [39].
In mice, the use of a mixture of mAbs directed against
different epitopes of IL-6 reduced the cytokine carrier effect
of a single mAb [40]. It has also been shown that immuniza-
tion with a modified IL-6 molecule leads to induction of a
polyclonal antibody response to IL-6, which is able to
neutralize fully the phenotype induced by chronic over-
production of human IL-6 in human IL-6 transgenic mice [41].
These observations suggest that use of antibodies with
multiple specificities for IL-6 may be more efficacious than
use of a single mAb. However, neither of these approaches is
readily applicable to treatment in humans.
At this point the development of an alternative strategy
became desirable, and a system to block the binding of IL-6
to the receptor was developed (Fig. 2). In a collaboration
between Chugai Pharmaceutical Co Ltd (Tokyo, Japan; now
a member of the Roche Group) and the Medical Research
Council Collaborative Centre (London, UK), a humanized anti-
human IL-6 receptor mAb was developed. A mouse mAb
against the human IL-6 receptor was generated from a mouse
immunized with human IL-6 receptor, as previously reported
[42]. In order to reduce the immunogenicity of the mouse
antibody and to prevent induction of neutralizing antibodies,
this mouse antibody was humanized to create tocilizumab
(previously named MRA) [43]. Tocilizumab has been
Available online http://arthritis-research.com/content/8/S2/S2
Figure 1
Feedback regulation in IL-6 signaling by SOCS. IL, interleukin; IL-6R,
interleukin-6 receptor; JAK, Janus activated kinase; SOCS,
suppressors of cytokine signaling; STAT, signal transducer and
activator of transcription.demonstrated to block the action of IL-6 without increasing
the IL-6 half life (as was seen with anti-IL-6 strategies); at the
same time there is an increase in the half-life of the antibody
(humanization of antibodies has been shown to have this
effect). Most importantly, the action of the soluble IL-6
receptor is also blocked. The soluble IL-6 receptor has been
shown to mediate many of the activities of IL-6, including
osteoclast formation, synovial fibroblast proliferation and
cartilage degradation [44-47].
Clinical studies have shown the utility of IL-6 receptor
blockade in Castleman’s disease [48]. Studies have also
demonstrated acceptable safety and significant efficacy in
trials in both adult rheumatoid arthritis and systemic onset
juvenile arthritis [49-52].
Conclusion
Because the effects of anti-IL-6 receptor antibody treatment on
the diseases were so dramatic, further studies of immune
functions and gene expression in patients before and after
treatment might provide important insights into the
pathogenesis of these diseases. The following papers further
investigate the specific effects of IL-6 biology in animal models
and in humans and the effects of blocking the IL-6 receptor.
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Figure 2
Blockade of IL-6 signals by anti-IL-6 receptor antibody (MRA, Tocilizumab).
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